Sequenom Inc. and Collaborators to Present New ClonoSIGHT™ Test Data at Annual Meeting of the American Society of Hematology
Published: Nov 07, 2013
Sequenta, Inc., and its collaborators from academic institutions around the world will share data demonstrating the validity and prognostic value of the ClonoSIGHT test for minimal residual disease (MRD) in four oral and 13 poster presentations, encompassing eight different blood cancer subtypes, at the annual meeting of the American Society of Hematology (ASH) being held December 7-10, 2013 in New Orleans, La.
Help employers find you! Check out all the jobs and post your resume.